HMicro picks up $10M+ to advance wireless system-on-a-chip tech

DNA computer

HMicro, which makes wireless system-on-a-chip biosensor tech, raised a $10.2 million Series C round. It will use the funding to drive the development and commercialization of its biosensor platform, disposable wireless patch and mobile and fixed location receiver devices.

Fremont, CA-based HMicro was founded in 2008 to develop a silicon-based wireless sensing platform and related products for medical companies, HMicro said in a statement. Its Reach Module platform includes a chip, biosensor patches and receiver devices for use in medical devices.

HMicro is co-developing wireless, clinical-grade devices for the monitoring of physiology, according to the company. Its first focus is a single-patient ECG device. Using its wireless technology, HMicro hopes to replace the wiring harness used in ECG--electrodes attached to the chest and leads connecting them to the patient monitor--with a much smaller wireless solution. HMicro will announce relationships with various partners “in the coming months,” said CEO Surendar Magar in the statement.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

OEM Partners, which will be commercializing Reach-based products, participated in the round, along with existing investors XSeed Capital, Seraph Group and Uniquest. HMicro previously raised $5.5 million in a 2014 Series B round.

“We are excited to expand our equity partnerships to firms who will be immediately leveraging our technology into their development initiatives and customer solution roadmaps,” Magar said in the statement. “Migrating clinical healthcare to the wireless domain is a huge challenge which we believe is best met by pooling resources from committed supply and OEM partners.”

Read more on

Suggested Articles

Medtronic has moved to acquire Avenu Medical, developers of a minimally invasive method of building the blood vessel access ports.

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.